Merck KGaA and Pfizer Inc. announced that data from a planned interim analysis of the phase III JAVELIN Ovarian 100 study of avelumab did not support the study's initial hypothesis, and therefore the alliance made the decision to terminate the trial in alignment with the independent Data Monitoring Committee.
The American Cancer Society and the Melanoma Research Alliance have partnered to support research by requesting grant applications involving interdisciplinary teams to better understand and manage metastasis of melanoma and other types of cancer.
The FY19 appropriation provides $20 million to the Department of Defense Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, retirees, their family members, and all women impacted by this disease. The DOD Congressionally Directed Medical Research Programs... […]
Lori PierceMichael ThompsonElizabeth MittendorfEthan BaschThe American Society of Clinical Oncology has elected Lori Pierce, a long-time member and volunteer, to serve as its president for the term beginning in June 2020. She will take office as president-elect during the ASCO annual meeting in Chicago in June 2019.
The Community Oncology Alliance announced long-time board member and volunteer Michael Diaz, a practicing medical oncologist at Florida Cancer Specialists & Research Institute, has been elected president of COA. He took office for a one-year term on Jan. 1.
José Baselga was asked to resign as one of the editors-in-chief of Cancer Discovery, a journal published by the American Association for Cancer Research.
Bristol-Myers Squibb Co. and Celgene Corp. have entered into a definitive merger agreement under which BMS will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.
Moffitt Cancer Center has recruited five research scientists:
Clovis Oncology Inc. said the European Union's European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
FDA has granted orphan drug designation to M7824, the first regulatory designation for the bifunctional immunotherapy, for the treatment of biliary tract cancer. The designation follows the recent presentation of the first clinical data for M7824 in BTC at the European Society of Medical Oncology congress in October.
